• 한국미생물학회:학술대회논문집
• /
• 한국미생물학회 1999년도 제39회 춘계학술발표대회
• /
• pp.59.1-59.1
• /
• 1999

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.234-234
• /
• 1994

최근 새롭게 조명된 생약에 관한 여러 연구를 통해, 기존의 항암제 보다는 더 효과적이고 인체에는 부작용이 적은 항암제를 개발해내기 위해 국내 자생 생약중 총 103 종류( 95 손 98종 )을 채집하였다. 이들 생약을 암세포주( L1210, P333 D$_1$)와 장상세포주(Vero)을 대상으로 MTT colorimetric assay를 실시하여 항종양성에 대해 알아보았다. 이들 세포주에 대한 $IC_{50}$/ 값으로 세포독성능을 알아보았다. 그리하여 정상세포주에는 적은 세포 독성능을 나타내면서, 암세포주에는 높은 세포 독성능을 나타내는 생약제 6종( BuOH 추출물 2종, MeOH) 추출물 4종 )을 선정하였다. 이중 항암활성능이 가장 높은 미역줄나무(Tripteryrium regelii)를 선택하여 유기용매별로 추출, 그 각각에 대한 세포 독성능이 가장 높게 나타난 2분획을 선택하여 기존에 시판중인 Adriamycin과의 병용 투여시의 세포 독성능의 상승효과를 확인 하였다. 즉 Adriamycin과의 단독 투여보다 복합 투여시에 암세포주에 대한 세포 독성능이 높아졌고, 정상세포주에 대한 독성이 감소되는 효과가 나타났다. 또한 in vitro 에서는 세포 독성능이 다소 적더라도 in vivo에서 면역학적 활성이 기대되는 생약제 3종을 선정하여 항암성분의 분리 및 정제를 하여 항암성에 대하여 알아보았다.

• 대한한방내과학회지
• /
• 제32권3호
• /
• pp.451-457
• /
• 2011

Progress : A 33 year old female patient diagnosed with left breast cancer stage II was admitted to EWCC (East-West Cancer Center) in November of 2009. She had planned chemotherapy. She was treated with herbal medicine, acupuncture, moxibustion and physiotherapy for a period of 4 months, from Nov 5th, 2009 to Feb 18th 2010. We evaluated the grade of chief complaints and performed blood tests periodically. Results : TKM alleviates symptoms induced by anticancer chemotherapy. Nausea, headache, dizziness and chemotherapyinduced peripheral neuropathy were reduced. Quality of life was also upward. Conclusions : This case study supports TKM's potential efficacy in treating breast cancer patients suffering from anticancer chemotherapy.

• Journal of Life Science
• /
• 제9권1호
• /
• pp.40-44
• /
• 1999

Glutathione S-transferase (GST) is a multifunctional protein that catalyzes the catalyzes the conjugation of glutathione with electrophilic compounds. It exists in a variety of isoenzy-matic froms with a wide range of substrate specificity and plays a pivotal role in detoxification of various drugs. In order to elucidate the GST-${\pi}$'s involvement of multidrug resistance (MDR) in drug-resistant tumor cell lines, we determined GST-${\pi}$ content by "1 step sandwich method". Consequently, adriamycin resistant cells of MCF-7 (MCF-7/ADM) have 7-fold increase of GST-${\pi}$ content than that of MCF-7 cells, while its {TEX}$IC_{50}${/TEX} was 116-fold greater than parent cell line. By northrn blotting, we compared whether MCF-7/ADM cells express GST-${\pi}$ mRNA. The GST-${\pi}$ mRNA expression in these cells was not inducible, but constitutive when treated for 24 h with a concentration of 0, 20, 200, and 2000 nM of adriamycin, respectively. Taken together, these results suggest that GST-${\pi}$ may not be directly associated with multidrug resistance in these human cancer cell lines.ell lines.

• 종양간호연구
• /
• 제10권1호
• /
• pp.10-18
• /
• 2010

Purpose: This study was intended to identify the patterns of fatigue and its related factors in patients with stomach cancer during chemotherapy. Methods: Thirty participants (24 males and 6 females) were recruited for this study which utilized a longitudinal and descriptive approach. The research instruments included the Revised Piper Fatigue Scale, Symptom Distress Scale, and Linear Analogue Self Assessment Scale. The participants received 5-FU and Adriamycin at the first week and 5-FU only at the second and third week. The instruments were measured six times in total. The data were analyzed using SPSS 17.0. Results: It was found that fatigue scores in patients with stomach cancer, receiving 5-FU and Adriamycin (FA) regimen, reached the highest level on the third day (F=9.37, p=.024) after the initial infusion, and decreased gradually afterward. The symptom and psychological distress scores illustrated very similar pattern. The concept of multidimensionality of fatigue in patients with stomach cancer was supported in this study, showing that all four dimensions of the scale were positively correlated. Conclusion: The results of this study provided useful information of patients with stomach cancer on fatigue and other related symptoms which they experienced during weekly scheduled chemotherapy with FA regimen.

• Toxicological Research
• /
• 제11권2호
• /
• pp.181-185
• /
• 1995

To know the mechanism of biphenyl dimethyl dicarboxylate (DDB) in the protection of chemically induced hepatotoxicity, the activity of glutamic pyruvic tran.saminase (GPT) and the level of lipid peroxidation metabolite (malondialdehyde, MDA) and ATP content in hepatocytes were determined in serum and primarily cultured hepatocytes. For in vibo study, rats were pretreated with DDB (300 mg/ kg, p.o.)for 7 days. DDB pretreatment efficiently reduced the elevation of serum GPT activity induced by carbon tetrachloride (1.6 ml/kg, s.c.) and acetaminophen administration (1500 mg/kg, i.p.). In ex vivo study, hepatocytes were isolated from the rats pretreated with DDB (300 mg/kg, p.o.)for 7 days and cultured for 12 hrs before inducing cytotoxicity with chemicals. The MDA formation and the GPT release induced by adriamycin $(1\times10^{-4} mg/ml)$ and cisplatin $(2\times10^{-4} mg/ml)$ were markedly decreased in the hepatocytes from the rats pretreated with DDB as compared to vehicle only. However, DDB pretreatment did not prevent the decrease of ATP contents of hepatocytes induced by cisplatin and adriamycin. In in vitro experiment, DDB was pretreated in primary cultured hepatocytes for 3 days. DDB enhanced the decreases of ATP contents induced by cisplatin and adriamycln. These results suggest that DDB may protect the hepatocytes from injury induced by hepatotoxlcants through inhibiting the lipid peroxidation.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권2호
• /
• pp.895-901
• /
• 2013

Resistance to induction of apoptosis is a major obstacle for bladder cancer treatment. Bcl-2 is thought to be involved in anti-apoptotic signaling. In this study, we investigated the effect of Bcl-2 overexpression on apoptotic resistance and intracellular reactive oxygen species (ROS) generation in bladder cancer cells. A stable Bcl-2 overexpression cell line, BIU87-Bcl-2, was constructed from human bladder cancer cell line BIU87 by transfecting recombinant Bcl-2 [pcDNA3.1(+)-Bcl-2]. The sensitivity of transfected cells to adriamycin (ADR) was assessed by MTT assay. Apoptosis was examined by flow cytometry and acridine orange fluorescence staining. Intracellular ROS was determined using flow cytometry, and the activities of superoxide dismutase (SOD) and catalase (CAT) were also investigated by the xanthinoxidase and visible radiation methods using SOD and CAT detection kits. The susceptibility of BIU87-Bcl-2 cells to ADR treatment was significantly decreased as compared with control BIU87 cells. Enhanced expression of Bcl-2 inhibited intracellular ROS generation following ADR treatment. Moreover, the suppression of SOD and CAT activity induced by ADR treatment was blocked in the BIU87-Bcl-2 case but not in their parental cells. The overexpression of Bcl-2 renders human bladder cancer cells resistant to ADR-induced apoptosis and ROS might act as an important secondary messenger in this process.

• BMB Reports
• /
• 제39권6호
• /
• pp.759-765
• /
• 2006

In this study, we investigate Nitric oxide synthase (NOS) expressions in adriamycin (ADR)-induced cadiomyopathy in rats. Sixty male Wistar rats were randomly divided into two main groups: control and ADR groups. Myocardial histopathological observation was performed; Expressions of 3 isoforms of NOS genes were examined by RT-PCR analysis; Expressions of 3 isoforms of NOS protein was assessed by Western blot analysis. Myocardium exhibited intensive morphological changes after 8 weeks of ADR treatment. The expression levels of inducible NOS (iNOS) gene and protein were significantly increased in ADR-treated rats after 8 weeks of treatment and then slightly increased at weeks 9 and 10. No significantly difference of neuronal NOS (nNOS) or endothelial NOS (eNOS) gene and protein were observed in the myocardium obtained from the control rats and ADR-injected rats at any time point. iNOS gene expression is selectively induced by ADR in heart. The upregulation of iNOS gene and protein may be somehow correlated with morphological changes seen in heart of rat treated with ADR.

• Applied Biological Chemistry
• /
• 제45권2호
• /
• pp.114-118
• /
• 2002

점액세균의 대사산물을 대상으로 새로운 항암활성물질을 탐색하는 과정에서 해양퇴적물에서 분리한 균주 JW111의 균체 추출액이 인체유래의 각종 암세포에 대해 강한 활성을 나타냄을 발견하고, 먼저 생산균주인 JW111이 Myxococcus stipitatus임을 확인한 후 그 대사산물을 분리, 정제하여 구조결정한 결과, Phenalamide $A_1$, $A_2E, $A_3$임을 밝혔다. 이들은 공시된 감수성 암세포에 대해 모두 우수한 활성을 나타내었으며, $IC_50$의 값은 $0.23{\sim}0.50{\mu}g/ml$이었다. 또한 이들은 Adriamycin의 내성 세포주에 대해서도 감수성 세포주와 동일한 활성을 나타내어 내성을 나타내지 않음이 확인되었다.

• Journal of Gastric Cancer
• /
• 제3권3호
• /
• pp.122-127
• /
• 2003

Purpose: The incidence rate and the mortality rate of gastric cancer have decreased in developed countries over the last several decades. On the other hand, they remain high in far eastern countries such as Korea, Japan, China and in many developing countries. The cure of patients with gastric carcinomas can be achieved mostly through complete surgical resection, but most gastric cancer patients are in advanced stages when diagnosed and have poor prognoses. therefore, the development of an effective systemic therapy is essential for far advanced gastric cancer patients. Until recently, the most commonly used combination chemotherapy was based on 5-flurouracil or cisplatin, but the results were not satisfactory, so recently etoposide, adriamycin and cisplatin (EAP-II) combination chemotherapy was introduced in patients with advanced gastric cancer. Early studies showed a high response rate and the ability to convert unresectable cases to resectable ones, but later studies couldn't duplicate the result. the purpose of this study was to evaluate the relative efficacy & toxicity of EAP-II chemotherapy and ELF chemotherapy which is based on 5-flurouracil. Materials and Methods: Between July 1992 and July 2002, sixty-five patients with inoperable advanced gastric cancer were enrolled for this study. Thirty-seven patient received EAP-II chemotherapy:etoposide (20 mg/$m^{2}$ IV for $1\∼5 days$), adriamycin (20 mg/$m^{2}$ IV for $1\∼5 days$) and cisplatin (20 mg/$m^{2}$ IV for $1\∼5 days$) and Twenty-eight patients receieved ELF chemotherapy : etoposide (100 mg/$m^{2}$ IV for $1\∼3 days$), leucovorin (20 mg/$m^{2}$ IV for $1\∼5 days$) and 5-FU (500 mg/$m^{2}$ IV for $1\∼5 days$). Each treatment schedule for each group was repeated every four weeks: EAP-II means 3.4 cycles per patient..ELF means 4.1 cycles per patient Results: Total respones rates were $5.4\%$ in the ELF group and $3.6\%$ in the EAP group (P-value>0.05). The median times to progression were 144 days in the ELF group and 92 days in the EAP-II group (P-value<0.05), and themedian overall survival times were 189 days in the ELF group and 139 days in the EAP-II group (P-value>0.05). The difference in the survival curves for the two regimens was not statistically significant. Non-hematologic toxicitis & hematologic toxicitis were more frequently observed for the EAP-II regimen. Anemia: $27.6\%$ in ELF vs $54\%$ in EAP-II; Leukopenia: $8.5\%$ in ELF vs $19\%$ in EAP-II; nausea & vomiting: $45.9\%$ in ELF vs $67.8\%$ in EAP-II. Conclusion: EAP-II regimen is not superior to ELF regimen in the tratment of inoperable advanced gastric cancer (J Korean Gastric Cancer Assoc 2003;3:122-127)